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6/j.bInterleukin-6 (IL-6) is a potent pleiotropic cytokine that regulates plasma cell (PC) growth via the IL-6 recep-
tor (IL-6R). We hypothesized that up-regulation of IL-6R in myeloma cells might confer the growth privilege
to myeloma cells over bone marrow (BM) hematopoietic cells.We investigated the frequency and prognostic
implication of increased copy number of the IL-6R gene by fluorescence in situ hybridization (FISH) in patients
with newly diagnosed multiple myeloma (MM). One hundred two patients with newly diagnosed MM were
enrolled. The FISH study for IL-6R was performed using a homemade bacterial artificial chromosome (BAC)
probe for IL6R at chromosome 1q21. FISH signals were counted among BM plasma cells sorted by cytoplas-
mic immunoglobulin light chain staining (cIg FISH). The amplification of IL-6R was detected in 53/102 patients
(52.0%). The 5-year overall survival (OS) rate of patients with IL-6R gene amplification was 41.3% versus
44.8% for those with a normal IL-6R (P 5 .425). In 44 patients treated with high-dose chemotherapy and
autologous stem cell transplantation (ASCT), patients with $3.1 copy numbers of IL-6R per PC showed
adverse 5-year OS compared to those with\2.1 copies of IL-6R gene (44.4% versus 78.0%, P 5 .024). In
multivariate analysis, the increase of IL-6R copy numbers (mean copy/PC $3.1) could be considered as an
independent prognostic factor for MM patients who underwent ASCT. The gain of the IL-6R gene was
frequent in myeloma, showing an association with adverse prognosis in myeloma patients treated with
ASCT. These findings suggest the potential role of IL-6R in myeloma cell growth and therapeutic implications
of the IL-6R blocker in the future.
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Multiple myeloma (MM) is a malignant disease of
clonal proliferation of plasma cells (PCs), ultimately
resulting in the organ damage [1]. During the develop-
ment of MM, multistep genetic changes are accumu-
lated, and the early stages of disease progress to more
advanced disease, frommonoclonal gammopathy of un-
known significance (MGUS) to smoldering myeloma,
and finally to symptomatic myeloma [2]. This spectrum
of diseases somewhat overlap, requiring the satisfaction
of clinical, pathological, and laboratory criteria for the
diagnosis of MM [3]. Unlike other hematopoietic ma-
lignancies, myeloma is unique in that myeloma cells
maintain dormant growth among normal hematopoi-
etic cells for a time, and then progressively become
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close intercommunication between the bone marrow
(BM) microenvironment [4]. The growth privilege of
myeloma cells over hematopoietic cells is the result of
the concerted action ofmyeloma cells and BMmicroen-
vironmental cells, which eventually results in bone de-
struction and increasing myeloma cell burden with
depletion of hematopoiesis. Recently, increasing evi-
dence supports the hypothesis that the BM microenvi-
ronment plays a key role in the proliferation, survival,
and drug resistance of clonal myeloma cells. Myeloma
cells per se produce several cytokines for their own sur-
vival, that can also stimulate myeloma growth, whereas
microenvironmental cells actively support the growth of
myeloma cells through the production of cytokines. In
such interactions, both plasma cell surface molecules,
receptors for cytokines, and their soluble forms could
play important roles [5]. Among cytokines with pivotal
roles in myeloma, the importance of interleukin-6
(IL-6) for the survival and growth of myeloma cells
has been investigated considerably [6]. IL-6 is a potent
pleiotropic cytokine that has a wide range of physiolog-
ical activities and plays pathological roles in various in-
flammatory diseases and malignancies [7]. IL-6 was
initially known as a factor promoting the differentiation
of B-lymphocytes into class-switched immunoglobulin
(Ig)-secreting plasma cells, during the development of
normal plasma cells. The development of MM is medi-
ated by the autocrine and paracrine secretion of IL-6
from both myeloma cells and BM stromal cells, leading
to cell proliferation and prevention of apoptosis. IL-6
signaling is mediated by its receptor (IL-6R) system,
a heterodimer complex that consists of an 80-kDa
ligand-binding chain (known as a-chain, or CD126)
and a 130-kDa signal transducing chain (known as
gp130, b-chain, orCD130). In addition, the free soluble
form of IL-6R (sIL-6R), which lacks the membrane and
intracytoplasmic domain of the IL-6R molecule, can
bind IL-6 and transduce a signal through the gp130.
Several studies have shown that the levels of IL-6 and
soluble IL-6R are associated with an unfavorable out-
come of MM [8-10], and the therapeutic approach to
block the IL-6 signal has been recently therapeutically
targeted for myeloma. A recently developed humanized
anti–IL-6R monoclonal antibody, which was approved
for the treatment of rheumatoid arthritis, is a possible
candidate of such new therapeutic agents [11].
In the present study, we hypothesized that an
increased copy number of the IL-6R gene might con-
fer the growth privilege to myeloma cells over normal
hematopoietic cells. In the present study, we evaluated
the copy number of the IL-6R gene by the fluorescence
in situ hybridization (FISH) technique using a bacterial
artificial chromosome (BAC) clone in Korean patients
with myeloma, and correlated it with the overall
survival (OS).MATERIALS AND METHODS
Patients
We studied a cohort of 102 newly diagnosed MM
patients treated at Seoul National University Hospital
between April 2001 and August 2006. Patients were
treated with various forms of therapy: 44 patients
(43.1%) underwent high-dose chemotherapy with autol-
ogous stem cell transplantation (ASCT) and the remain-
ing 58 patients (56.9%) received only chemotherapywith
regimens based on vincristine and dexamethasone, tha-
lidomide,melphalan, cyclophosphamide, or bortezomib.
Among all of the patients, 59 patients (57.8%) died. The
median follow-up of the surviving patients was 57.5
months (range: 44.8-86.5 months).
In all of the cases studied, the mononuclear cells
from initial BM aspirates were fixed with Carnoy’s
solution and stored at 270C for further analysis. The
following information was gathered for each patient:
date of diagnosis and start of therapy; age; sex; ethnicity;
hemoglobin level; platelet count; level and type of para-
protein; and serum levels of calcium, creatinine, albu-
min, lactate dehydrogenase (LDH), b2-microglobulin,
and C-reactive protein (CRP). Stage was assessed
according to the International Staging System (ISS)
[12], and the Durie-Salmon system [13]. Furthermore,
we recorded the percentage of BM plasma cell infiltra-
tion, conventional cytogenetic results of BM cells by
G-banding, and the number of osteolytic lesions. The
BM samples were all collected with informed consent,
and the study was reviewed and approved by the institu-
tional review board of Seoul National University
College of Medicine.FISH
Bioinformatic information available at the Website
of the National Center for Biotechnology Information
(NCBI; http://www.ncbi.nlm.nhi.gov) was utilized to
select appropriate BAC clones for the FISH study of
the IL-6R gene at chromosome 1q21. A BAC clone
RP11-350G8 (BACPAC Resources, Oakland, CA),
which was with a size of about 200,000 base pairs (bp)
and contains IL6R, ATP8B2,AQP10,DKFZp434M202,
and LOC126669 genes, was selected and prepared.
The BAC was grown in selective media, and the DNA
was prepared with a BAC plasmid purification kit
(Qiagen Inc., Valencia, CA). The FISH probe was
labeled by a nick translation reaction. Briefly, 1 mL of
extracted BAC DNA was mixed with 0.2 mM of
dUTP-SpectrumOrange (Vysis, Downers Groove,
IL), 0.1 mM of dTTP, 0.1 mM each of dATP, dCTP,
dGTP, nick translation buffer, and nick translaton en-
zyme (Vysis). The reaction was carried out at 15C
for 4 hours and stopped by heating in a 70C water
bath for 10 minutes. Five microliters of the nick
812 Biol Blood Marrow Transplant 17:810-820, 2011S. Y. Kim et al.translation reaction mixture was added to 2 mg of Cot1-
DNA (Vysis) to block the repetitive DNA sequences.
After ethanol precipitation, the labeled DNA pellet
was resuspended in 7 mL of hybridization buffer (Vysis)
and 3 mL of purified water. The probe was denatured by
heating at 73C for 5 minutes.
Interphase FISH was performed on stored patient’s
BM aspiration specimens using a modification of the
simultaneous k/l immunoglobulin light chain cytoplas-
mic stainingmethod (cIg FISH) according to the proce-
dure described elsewhere [14]. Five microliters of 1:20
dilution of 1:1 mixture of polyclonal antihuman k
(Clone F0198; DakoCytomation, Glostrup, Denmark),
and antihuman l (Clone F0199; Dako) was added with
incubation for 40minutes in the dark humidified cham-
ber. Slides were washed 2 times in phosphate-buffered
saline (PBS) and dried. Slides were stained with FISH
probes and counterstained with DAPI, and then fluo-
rescence signals were analyzed by use of a fluorescence
microscope (Zeiss, G€ottingen, Germany). Interphase
FISH signals were evaluated in 100 plasma cells. If at
least 3 copies were seen in at least 10% of clonal plasma
cells, it was considered evidence of the copy number
gain. To investigate the effects of the magnitude of
the copy number gain on the prognosis, patients were
divided into 3 categories by the mean copy number of
IL-6R gene per a clonal PC: (1) patients without copy
number gain (mean copy number \2.1); (2) those
with mean copy number from 2.1 to 3.1; and (3) those
with mean copy number of 3.1 or greater.
Other common chromosomal abnormalities were
also investigated using commercial FISH probes: an
LSI dual-color, break-apart probe for IGH transloca-
tions; a dual color, dual-fusion probe for
t(11;14)(q13;q32); a dual color, dual-fusion probe for
t(4;14)(p16;q32); PAX5 (9p13) probe; LSI 13 (RB1)
13q14 probe; LSI p53 (17p13.1) SpectrumOrange
probe; LSI D20S108 (20q) probe; and LSI 1p36/1q25
probe (all from Abott Molecular/Vysis, Des Plaines,
IL). The results of the FISH studies were recorded ac-
cording to the StandingCommittee onHumanCytoge-
netic Nomenclature’s International System for Human
Cytogenetic Nomenclature (ISCN) [15].Statistical Analysis
The chi-square test and the Fisher exact test were
used to compare categoric variables. Estimates of
progression-free survival (PFS) and OS were estimated
using theKaplan-Meiermethod, and differences among
survival curves were analyzed using the log-rank test.
Cox proportional hazards regression analysis was used
to develop a multivariate model of prognostic factors
considering those factors that were associated with sur-
vival. Statistical analyses were performed using SPSS
version 12.0 (SPSS Inc., Chicago, IL). P values\.05
were considered statistically significant.RESULTS
Baseline Patient Characteristics
The baseline characteristics of the patients are
summarized in Table 1. All of the patients were
Korean, and the median age of the patients was 60.7
years (range: 35.2-79.8). When we compared patients
who underwent ASCT and those who were treated
with chemotherapy only (CTx only), the ASCT group
of patients were younger (P\ .001) and tended to have
lower mortality (P\ .001). Other clinical characteris-
tics were not significantly different (Table 1).Prevalence of the Copy Number Change of the
IL-6R Gene and Other Genetic Abnormalities
The copy number gain of the IL-6R gene was
detected in 53/102 patients (52.0%). When mean
copy numbers per a clonal plasma cell were calculated
in patients with IL-6R gene copy number gain, the
mean copy number of IL-6R per PC ranged from 2.2
to 7.2, with a median of 3.0. There were 28 patients
(27.5%) for whom the mean copy number of IL-6R
was within 2.1 to 3.1, and 25 (24.5%) with 3.1 or
more copies of the IL-6R gene (Table 2).
The t(14q32) was detected by interphase FISH in
31 patients (30.4%). Among them, t(4;14) was detected
in 7 patients (6.9%), and t(11;14) was detected in 12
(11.8%). The PAX5 (9p13) rearrangement was not
observed in all patients, and the RB1 (13q14) and
TP53 (17p13) deletion was detected in 31 (30.4%)
and 10 (9.8%) patients, respectively. There was no
difference in the incidence of cytogenetic abnormali-
ties between patients groups when classified by treat-
ment (Table 2).Association between Change of IL-6R Gene
Copy Number and Clinical and Biological
Characteristics
Patients with increased IL-6R copy number
tended to be females (P5 .058) with high levels of cre-
atinine (P 5 .097), low levels of platelets (P 5 .111),
and a high incidence of abnormal karyotypes as defined
by G-banding (P 5 .081), though the differences in
these parameters were not statistically significant
(Table 3). We also observed that the incidence of
t(14q32) detected by interphase FISH was not signifi-
cantly different between patients with an increased
copy number of the IL-6R gene and those with a nor-
mal IL-6R copy number. The RB1 deletion and TP53
deletion were detected in 35.9% and 15.1% of patients
with the increased copy number of the IL-6R gene,
and in 24.5% and 4.0% of those with normal IL-6R
copy number (P 5 .213 and P 5 .062, respectively).
Table 1. Baseline Characteristics of All Patients and of Subgroups Divided by Treatment
Characteristics
No. of Patients/Total No. (%)
Total ASCT CTx Only P*
Age $65 years 33/102 (32.4) 1/44 (2.3) 32/58 (55.2) <.001
Male sex 61/102 (59.8) 26/43 (59.1) 35/58 (60.3) .898
IgG subtype 59/99 (59.6) 25/43 (58.1) 34/56 (60.7) .796
IgA subtype 21/99 (21.2) 10/43 (23.3) 11/56 (19.6) .663
Light chain only 19/99 (19.2) 8/43 (18.6) 11/56 (19.6) .975
b2-MG $3.5 (mg/L) 55/102 (53.9) 24/44 (54.6) 31/58 (53.5) .912
CRP $2 (mg/L) 21/102 (20.6) 6/44 (13.6) 15/58 (25.9) .131
Creatinine $2 (mg/dL) 22/102 (21.6) 7/44 (15.9) 15/58 (25.9) .226
LDH $230 (IU/L) 55/102 (53.9) 10/44 (22.7) 21/58 (36.2) .143
Albumin <3.5 (g/dL) 55/102 (53.9) 26/44 (59.1) 29/58 (50.0) .362
Hb <10 (g/dL) 49/102 (48.0) 21/44 (57.7) 28/58 (48.3) .956
PLT <130 (109/L) 19/102 (18.6) 10/44 (22.7) 9/58 (15.5) .354
Calcium $10 (mg/dL) 26/102 (25.5) 11/44 (25.0) 15/59 (25.4) .921
International Staging System
Stage I 47/102 (46.1) 20/44 (45.5) 27/58 (46.6) .912
Stage II 20/102 (19.6) 11/44 (25.0) 9/58 (15.5) .232
Stage III 35/102 (34.3) 13/44 (29.6) 22/58 (37.9) .377
Durie-Salmon Stage
DS Stage I 17/102 (16.7) 4/44 (9.1) 13/58 (22.4) .074
DS Stage II 25/102 (24.5) 12/44 (27.3) 13/58 (22.4) .572
DS Stage III 60/102 (58.8) 28/44 (63.6) 32/58 (55.2) .389
$3 Lytic bone lesions 41/102 (40.2) 18/44 (40.9) 23/58 (39.7) .898
Abnormal karyotype† 19/95 (20.0) 6/42 (14.3) 13/53 (24.5) .215
Hyperdiploidy† 15/95 (15.8) 5/42 (11.9) 10/53 (18.9) .355
BM-PC $33% 41/102 (40.2) 17/44 (38.6) 24/58 (41.4) .779
Death 59/102 (57.8) 14/44 (31.8) 45/58 (77.6) <.001
ASCT indicates autologous stem cell transplantation; CTx, chemotherapy; Ig, immunoglobulin; b2-MG indicates serum b2-microblobulin; CRP,
C-reactive protein; LDH, serum lactate dehydrogenase; Hb, hemoglobin; DS, Durie-Salmon; BM-PC, plasma cells in bone marrow aspirates.
*P values by chi-square test between ASCTand CTx only groups.
†Abnormal karyotype and hyperdiploidy were defined by G-banding.
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Other Genetic Abnormalities on Prognosis
There were no significant differences in PFS and
5-year OS between patients with an increased copy
number of the IL-6R gene versus those with a normal
copy number. The median PFS of patients with 1q21/
IL6R gainwas 23.7months versus 38.4months for those
without 1q21/IL6R gain (P 5 .085). The 5-year OS in
patients with the increased copy number of the IL-6RTable 2. Summary of Interphase FISH Results for IL-6R and Other
FISH Total
1q21/IL6R gain 53/102 (52.0)
2.1-3.1 copies/PC† 28/102 (27.5)
$3.1 copies/PC† 25/102 (24.5)
IGH (14q32) translocation 31/102 (30.4)
t(4;14)(p16;q32) 7/102 (6.9)
t(11;14)(q13;q32) 12/102 (11.8)
PAX5 (9p13) translocation 0/102 (0)
RB1 (13q14) deletion 31/102 (30.4)
TP53 (17p13) deletion 10/102 (9.8)
20q deletion 8/102 (7.8)
1p36/1q25 amplification 38/102 (37.3)
ASCT indicates autologous stem cell transplantation; CTx, chemotherapy; FIS
*P values by chi-square test between ASCTand CTx only groups.
†Mean copy number of IL-6R gene per plasma cell detected by FISH.gene was 41.3% compared with 44.8% in patients with
normal IL-6R copy number (P 5 .425) (Figure 1A).
When the 5-year OS was compared according to the
other recurrent genetic abnormalities, patients with
t(14q32) demonstrated a poorer prognosis than patients
lacking t(14q32) (29.0% vs. 49.0%, P 5 .007), and
patientswith t(4;14)hada5-yearOSof14.3%compared
with 44.8% in those lacking t(4;14) (P 5 .002)
(Figure 1B and C). Patients with t(4;11), RB1 deletion,Common Abnormalities
No. of Patients/Total No. (%)
ASCT CTx Only P*
19/44 (43.2) 34/58 (58.6) .122
10/44 (22.7) 18/58 (31.0) .352
9/44 (20.5) 16/58 (27.6) .407
9/44 (20.5) 22/58 (37.9) .057
2/44 (4.6) 5/58 (8.6) .420
6/44 (13.6) 6/58 (10.3) .609
0/44 (0) 0/58 (0) NA
12/44 (27.3) 19/58 (32.8) .551
3/44 (6.8) 7/58 (12.1) .377
4/44 (9.1) 4/58 (6.9) .683
15/44 (34.1) 23/58 (39.7) .565
H, fluorescence in situ hybridization; PC, plasma cell; NA, not assessed.
Table 3. Baseline Patient Characteristics and Interphase
FISH Results According to the IL-6R Copy Number Change
Characteristics
No. of Patients/Total No. (%)
No 1q21/IL6R Gain* 1q21/IL6R Gain *P
Age $65 years 15/49 (30.6) 18/53 (34.0) .718
Male sex 34/49 (69.4) 27/53 (50.9) .058
IgA subtype 7/46 (15.2) 14/53 (26.4) .174
Light chain only 10/46 (21.7) 9/53 (17.0) .549
b2-MG $3.5 (mg/dL) 28/49 (57.1) 27/53 (50.9) .530
CRP $2 (mg/dL) 10/49 (20.4) 11/53 (20.8) .966
Creatinine $2 (mg/dL) 7/49 (14.3) 15/53 (28.3) .086
LDH $230 (IU/dL) 12/49 (24.5) 19/53 (35.9) .213
Albumin <3.5 (g/dL) 24/49 (49.0) 31/53 (58.5) .336
Hb <10 (g/dL) 23/49 (46.9) 26/53 (49.1) .831
PLT <130 (10/L) 6/49 (12.2) 13/53 (24.5) .111
Calcium $10 (mg/dL) 12/49 (24.5) 14/53 (26.4) .824
ISS stage I 21/49 (42.9) 26/53 (49.1) .530
ISS stage II 13/49 (26.5) 7/53 (13.2) .090
ISS stage III 15/49 (30.6) 20/53 (37.7) .449
>3 Lytic bone lesions 21/49 (42.9) 20/53 (37.7) .598
Abnormal karyotype† 6/47 (12.8) 13/48 (27.1) .081
Hyperdiploidy† 6/47 (12.8) 9/48 (18.8) .424
BM-PC $33% 20/49 (40.8) 21/53(39.6) .902
IGH (14q32) translocation 13/49 (26.5) 18/53 (34.0) .415
t(4;14) 2/49 (4.1) 5/53 (9.4) .285
t(11;14) 6/49 (12.2) 6/53 (11.3) .885
RB1 (13q14) deletion 12/49 (24.5) 19/53 (35.9) .213
TP53 (17p13) deletion 2/49 (4.0) 8/53 (15.1) .062
Death 28/49 (57.1) 31/53 (58.5) .891
Ig indicates immunoglobulin; b2-MG indicates serum b2-microblobulin;
CRP, C-reactive protein; LDH, serum lactate dehydrogenase; Hb, hemo-
globin; ISS, International Staging System; BM-PC, plasma cells in bone
marrow aspirates.
*P values by chi-square test between patients with or without 1q21/IL6R
gain.
†Abnormal karyotype and hyperdiploidy were defined by G-banding.
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the 5-yearOS comparedwith those lacking each cytoge-
netic abnormality (Figure 1D-F).
Prognostic Impact of IL-6R Gene Copy Number
Gain According to Treatment and Other
Accompanied Prognostic Markers
Among the 44 patients treated with ASCT, patients
with $3.1 copy numbers of the IL-6R gene had worse
PFS compared with those with\2.1 copy numbers of
IL-6R (median PFS, 13.6 versus 54.8 months, P 5
.045). In contrast, the 5-year PFS were not significantly
different between patients withmean 2.1-3.1 copy num-
bers of IL-6R and\2.1 copies of IL-6R gene (median
PFS, 46.6 versus 54.8 months, P 5 .253) (Figure 2A).
The 5-year OS of patients with$3.1 IL-6R copies was
44.4%, which was significantly shorter than the 5-year
OS of those with\2.1 copies (78.0%, P5 .024). How-
ever, the 5-year OS was similar between patients with
means of 2.1-3.1 copies and\2.1 copies of the IL-6R
gene (90.0% versus 78.0%, P 5 .570). In contrast to
the prognostic implication of IL-6R copy number
among patients with ASCT, among the 59 patients
treated with chemotherapy alone, patients with $3.1
copies as well as those with 2.1-3.1 copies showed nodifference in survival compared to patients with\2.1
copies (median PFS, at least 3.1 copies versus up to 2.1
copies, 26.5 versus 12.0 months, P 5 .564; 5-year OS,
31.3% versus 14.6%, P5 .719) (Figure 2C and 2D).
Among 42ASCTpatients without t(4;14), the 5-year
OS was significantly different between patients with
$3.1 copies of IL-6R (50.0%) and in those with\3.1
copies (80.6%) (P 5 .033). There were only 2 ASCT
with t(4;14), and 1 patient with$3.1 copies expired after
21.2months of follow-up, and a patient with\3.1 copies
has survived up to 52.4 months (Figure 3A). Among
20 ASCT patients with b2-microglobuling level
\3.5 mg/L, the 5-year OS was shorter in patients with
$3.1 copies of IL-6R compared to those with \3.1
copies (66.7% versus 100%; P 5 .017). Among 24
ASCT patients with b2-microglobulin level $3.5 mg/
L, the 5-year OS of patients with $3.1 copies were also
tended to be shorter than those with \3.1 copies
(33.3% versus 60.2%, P5 .067) (Figure 3B).
In a Cox proportional hazard analysis of a total 102
newly diagnosed patients, gain in IL-6R copy number
was not an independent prognostic factor for OS with
the hazard ratio (HR) of 1.06 (95% confidence interval
[CI], 0.72-1.57, P 5 .755); instead, treatment with
ASCT and b2-microglobulin level were analyzed as
independent prognostic factors (Table 4). In a multi-
variate analysis of 44 patients treated with ASCT,
1q21/IL6R gain emerged as an independent prognostic
factor (HR, 2.51; 95% CI, 1.13-5.54; P5 .023), along
with the b2-microglobulin level (HR, 19.17; P5 .004)
(Table 5).DISCUSSION
This study demonstrates that a gain in copy number
of the IL-6R gene (1q21) is the most common abnor-
mality in patients with myeloma and is detected in
about 50% ofMMpatients by FISH.Moreover, the in-
creased IL-6R gene copy number is shown to be associ-
ated with an adverse prognosis in myeloma patients
treatedwithASCT,butnot in those treatedwithchemo-
therapy alone. The previous studies reported that chro-
mosome 1q21 gain was 1 of the most common genetic
abnormalities in MM [16-18], and the gain of 1q21
was associated with poor prognosis in MM patients
[19-21]. However, the molecular mechanisms of 1q21
gain are not been fully understood, and whether it
is a cause or a consequence of disease progression,
reflecting chromosomal instability, remains unknown
[20]. High-resolution mapping and gene expression
profiling studies have suggested that the 1q21 gain
may have pathogenic significance related to the in-
creased expression of genes within this region. Some
have indicated a cell cycle–associated gene CKS1B as
a candidate gene located on 1q21 affecting the poor
prognosis, using FISH or a gene expression profiling
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Figure 1. A Kaplan-Meier analysis of OS is displayed in relation to (A) increased IL-6R copy number, (B) t(14q32), (C) t(4;14), (D) t(11;14), (E) RB1
deletion, and (F) TP53 deletion.
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Figure 2. Survival according to the mean IL-6R gene copy per plasma cell. (A) PFS and (B) OS in patients who underwent ASCT. (C) PFS and (D) OS in
patients that received chemotherapy only.
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patients with 1q21 gain had the worst prognosis
regardless of expression levels of CKS1B, when the
survival of patients with combinations of 1q21 gain
and CKS1B expression level were compared [21]. The
present study targeted the IL-6R located on the 1q21 re-
gion, suggesting the IL-6R amplification as a candidate
gene for a prognostic factor.
In this study, a gain in IL-6R gene copy number had
no significant association with other genetic abnormali-
ties, including t(4;14), del(13)(q14), or del(17)(p13).
Some previous studies reported a close associations of
1q21 gain and known high-risk factors such as t(4;14),
and proliferation markers. They inferred that 1q21
gain reflected an underlying more clonally advanced
and genetically unstable disease, because of the strongassociation with poor prognostic genetic markers, and
the impact on survival was postulated to be mediated
by the close relationship with high-risk cytogenetic ab-
normalities [21].Considering that thesepoorprognostic
genetic markers were detected with much lower fre-
quencies than 1q21 gain, it might be insufficient to
explain the prognostic relevance of 1q21 gain only in
association with other genetic abnormalities. Further-
more, 1q21 gain was found to be an independent prog-
nostic factor in multivariate analysis, both in this
study and some previous studies [19,20]. However, we
suggest the adverse prognosis in patients with IL-6R
gain could result from the high proliferative activity
caused by increased Il-6 uptake on the cell surface with
increased IL-6R molecules. We did not identify the in-
creased IL-6R receptor molecules on primary myeloma
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Figure 3. A Kaplan-Meier analysis of OS among patients treated with autologous stem cell transplantation (ASCT) is displayed (A) according to t(4;14)
and the copy number change of IL-6R and (B) according to the b2-microglobulin (b2-MG) level and the copy number change of IL-6R.
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firmationof increased expression of IL-6Rat the protein
or mRNA level.
IL-6 is a key growth factor involving the growth
and survival of myeloma cells. IL-6 is predominantly
produced and secreted by bone marrow stromal cells
(BMSCs) and osteoblasts, and is regulated both by
autocrine as well as paracrine loops. It is thought to
trigger MM cell growth and survival by triggering
activation of RAS/MEK/MAPK, JAK/STAT3, and
PI3K/Akt signaling pathways [28]. In addition to
MM cell growth and survival, IL-6 also triggers drug
resistance via continued IL-6 production in the
BMSCs to counteract the apoptotic pathway activation
by antimyeloma drugs [29]. The role of IL-6 in the
development and metastasis of tumors has also been
reported in other tumors, such as neuroblastoma, in
which IL-6 synthesized by mesenchymal stem cellsTable 4. Multivariate Cox Analysis of Progression-Free Survival (PF
MM Patients
Characteristics n (%)
PFS
HR 95% CI
1q21/IL6R gain* 53 (52.0) 1.34 0.97-1.86
ASCT 44 (43.1) 0.44 0.27-0.73
Hb < 10 g/dL 49 (48.0) 0.87 0.50-1.51
b2-MG $3.5 mg/L 55 (53.9) 3.09 1.73-5.52
BM-PC $33% 41 (40.2) 1.45 0.80-2.64
Hyperdiploidy† 15 (15.8) 1.49 0.77-2.89
t(4;14) 7 (6.7) 2.00 0.79-5.03
t(11;14) 12 (6.7) 1.56 0.75-3.24
RB1 (13q14) deletion 31 (30.4) 0.75 0.44-1.30
HR indicates hazard ratio; CI, confidence interval; ASCT, autologous stem cell
C-reactive protein; BM-PC, plasma cells in bone marrow aspirates.
*Mean copy number of the IL-6R gene per plasma cell detected by FISH (divid
†Hyperdiploidy was defined by G-banding.(MSCs) directly stimulates the survival and prolifera-
tion of IL-6R–positive neuroblastoma metastases [30].
Aside from the gene level, the protein-level investi-
gation of elevated IL-6 or soluble IL-6R in MM in the
context of a possible prognostic factor has been
reported by several studies, most of which showed
that the IL-6 and IL-6R levels were associated with
a poor prognosis in MM patients [8-10,31]. In these
studies, the elevated level of soluble IL-6Rwas revealed
to be a weak but significant prognostic factor, improv-
ing the prognostic value of b2-microglobulin [8,9,31].
However, there are also a few other studies that have
reported controversial data [32-34]. One report
showed that aberrant expression of IL-6R (CD126)
was only observed in myeloma cells, but not in normal
plasma cells; however, the expression was not corre-
lated with advanced disease or prognosis [32]. In
another study, the lower PC surface expression ofS) andOverall Survival (OS) in a Total of 102 Newly Diagnosed
OS
P HR 95% CI P
0.078 1.06 0.72-1.57 .755
0.001 0.19 0.10-0.37 <.001
0.619 0.67 0.34-1.31 .241
<0.001 3.17 1.62-6.17 .001
0.224 1.70 0.80-3.60 .169
0.238 1.58 0.74-3.39 .242
0.142 2.34 0.84-6.54 .105
0.233 1.11 0.45-2.73 .824
0.312 0.51 0.26-1.02 .055
transplantation; Hb, hemoglobin; b2-MG, serum b2-microblobulin; CRP,
ed by <2.1, 2.1-3.1, $3.1 copies/PC).
Table 5. Multivariate Cox Proportional Hazards Analysis of Progression-Free Survival (PFS) and Overall Survival (OS) in 44 Pa-
tients Treated with High-Dose Chemotherapy and Autologous Stem Cell Transplantation (ASCT)
Characteristics n (%)
PFS OS
HR 95% CI P HR 95% CI P
1q21/IL6R gain* 19 (43.2) 1.80 1.10-2.93 0.019 2.51 1.13-5.54 .023
Hb <10 g/dL 21 (57.7) 0.68 0.25-1.85 0.450 0.70 0.17-2.91 .627
b2-MG $3.5 mg/L 24 (54.6) 4.06 1.42-11.63 0.009 19.17 2.52-145.64 .004
BM-PC $33% 17 (38.6) 1.22 0.48-3.13 0.680 3.83 0.86-17.12 .079
Hyperdiploidy† 5 (11.9) 1.38 0.34-5.54 0.653 0.34 0.03-4.10 .396
t(4;14) 2 (4.6) 1.57 0.27-9.17 0.618 0.34 0.03-4.28 .404
t(11;14) 6 (13.6) 1.86 0.55-6.30 0.320 0.87 0.15-5.05 .874
RB1 (13q14) deletion 12 (27.3) 0.67 0.24-1.87 0.445 0.16 0.02-1.28 .084
HR indicates hazard ratio; CI, confidence interval; Hb, hemoglobin; b2-MG, serum b2-microblobulin; CRP, C-reactive protein; BM-PC, plasma cells in
bone marrow aspirates.
*Mean copy number of the IL-6R gene per plasma cell detected by FISH (divided by <2.1, 2.1-3.1, $3.1 copies/PC).
†Hyperdiploidy was defined by G-banding.
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features [34]. These findings suggest that the patterns
of expression and regulation of soluble/membrane-
bound IL-6R might be complex when a copy number
gain of the IL-6R gene is present, and more intensive
investigations are needed.
A novel finding of this study is that the adverse
impact of the IL-6R gain was observed only in the pa-
tients treated with ASCT, but not in those who treated
with chemotherapy alone. Limited data are available
on the prognostic effects of 1q21 gain in patients
treated with conventional or novel chemotherapeutic
agents without transplantation, because most of the
previous studies were conducted on the patient cohorts
treated with high-dose chemotherapy and ASCT
[19-21,25,27]. One pilot study conducted on the
bortezomib-treated patient group reported that the
PFS and OS was similar for 1q21 gain positive and
negative relapsed/refractory MM patients [35]. These
findings might be explained if the impact of 1q21 is
not strong enough to overcome the drug effects. On
the contrary, another possible explanation is that the
dramatic changes in the microenvironment of BM af-
ter transplantation are related to the prognostic impact
of 1q21/IL6R gain in MM patients who underwent
ASCT, but not in patients treated with chemotherapy
alone. We suggest that an increased copy number of
IL-6R onmyeloma cells endowsmore powerful uptake
of IL-6, yielding a growth privilege. Consequently,
myeloma cells with an increased copy number of IL-
6R can regrow more easily in the presence of the
same amount of Il-6R, compared to those with a nor-
mal copy number of IL-6R. For more confirmatory
answers, further studies will be needed.
The detection of the IL-6R gene copy number by
FISH is quick and efficient, and has several advantages
over other techniques for measuring IL-6R gene am-
plification or overexpression of mRNA or protein,
such as karyotyping by conventional G-banding,
mRNA expression profiling, measurement of the solu-
ble receptor level, or flow cytometric analysis. Plasmacells are mature cells, which makes it more difficult
to detect cytogenetic changes using conventional
G-banding methods. Cytogenetic detection by inter-
phase FISH does not require cell culture procedures
to induce cell divisions and could be used for follow-
up as well as diagnosis of patients with MM [36].
With the FISH technique, the quantitative results of
copy number after sorting of plasma cell population
is also possible. Considering that IL-6R is increased
in many pathological conditions other than myeloma,
the detection of plasma cell with amplification of IL-
6R might be useful. In addition, if the quality of the
bone marrow aspiration is poor, the FISH analysis
could be performed on the bone marrow biopsy spec-
imen.
The detection of genetic changes is important, not
only because of their association with clinical prognosis,
but alsobecause theycanbeused aspotential therapeutic
targets. IL-6 has been known to be central to the patho-
genesis of myeloma, and inhibiting IL-6 signaling is of
therapeutic interest, particularly with the development
of anti-IL6 or IL-6R monoclonal antibodies [37]. Such
antibodies have been shown to have cytostatic effects
onmyeloma cells in vitro [11] and to enhance the antitu-
mor activity of other antimyeloma drugs in vivo by at-
tenuating chemoresistance [38]. These findings
suggest the potential role of IL-6R in myeloma cell
growth and support the therapeutic implication of IL-
6R blockers in the future. Furthermore, considering
the prognostic patterns of the patients in this study,
one might suggest that the patient group with the base-
line IL-6Rgenecopynumbergain and subsequent treat-
ment with ASCT could be considered possible
candidates that would benefit from anti–IL-6R therapy.
Our study has several limitations. First, this study
was a single-center, retrospective study with a limited
evidence level. Second, because of the small number
of patients with heterogeneous therapeutic strategies,
the statistical power was low. Third, the expression
of IL-6R at mRNA and protein level was not deter-
mined, and the correlation of the IL-6R gene copy
Biol Blood Marrow Transplant 17:810-820, 2011 819Interleukin-6 Receptor in Myelomanumber gain and IL-6R expression level was not ana-
lyzed. Further investigation of copy number gain and
overexpression of IL-6R with well-established animal
models and clinical study of randomized prospective
design on larger MM patient cohorts are required,
not only to clearly confirm the pathogenetic and prog-
nostic role of IL-6R in myeloma, but also to determine
the patient group for whom treatment with IL-6R
blocking would be most effective.
In conclusion, the gain of IL-6R gene is frequent in
myeloma and is an independent adverse prognostic
factor in myeloma patients treated with ASCT. These
results suggest the potential therapeutic role of IL-6R
blockers in patients with ASCT.ACKNOWLEDGMENTS
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